Engineered immune cells take on tough lung cancer in early trial
NCT ID NCT07564401
First seen May 09, 2026 · Last updated May 22, 2026 · Updated 3 times
Summary
This study tests a new treatment called DJI136, which uses a patient's own immune cells (T-cells) that are modified to target a protein (DLL3) found on small cell lung cancer cells. The trial is for adults with extensive-stage small cell lung cancer that has worsened after standard treatments. The main goals are to find the safest dose and to see if the therapy can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Novartis Investigative Site
RECRUITINGSingapore, 168583, Singapore
Conditions
Explore the condition pages connected to this study.